Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis

Biochemical and Biophysical Research Communications

Volumn 431, Issue 3, 2013, Pages 450-455

  Li, Yue Chun ^a   Luo, Qin ^a   Ge, Li Sha ^a   Chen, Yi He ^a   Zhou, Na Dan ^a   Zhang, Teng ^a   Guan, Xue Qiang ^a   Lin, Jia Feng ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Carvedilol; Cytokines; Ivabradine; Myocarditis; Nitric oxide

Indexed keywords

CARVEDILOL; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; IVABRADINE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MYOCARDITIS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; BENZAZEPINES; CARBAZOLES; COXSACKIEVIRUS INFECTIONS; CYTOKINES; GENE EXPRESSION; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROPANOLAMINES;

ANIMALIA; COXSACKIEVIRUS; MURINAE;

EID: 84873723928     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.147     Document Type: Article

References (31)

1. Seong I.W., Choe S.C., Jeon E.S. Fulminant coxsackieviral myocarditis. N. Engl. J. Med. 2001, 345:379.
2. Heymans S. Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools. Eur. Heart J. 2007, 28:1279-1280.
3. Perret-Guillaume C., Joly L., Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog. Cardiovasc. Dis. 2009, 52:6-10.
4. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur. Heart J. 2005, 26:2259-2268.
5. Sajadieh A., Nielsen O.W., Rasmussen V., et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur. Heart J. 2004, 25:363-370.
6. f-channel blockade and beta-receptor blockade. Hypertension 2012, 59:949-957.
7. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012, 33(2012):1787-1847.
8. Nishio R., Shioi T., Sasayama S., et al. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J. Am. Coll. Cardiol. 2003, 41:340-345.
9. Yue-Chun L., Li-Sha G., Jiang-Hua R., et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J. Cardiovasc. Pharmacol. 2008, 51:92-98.
10. Yue-Chun L., Li-Sha G., Peng-Lin Y., et al. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. Eur. J. Pharmacol. 2010, 640:112-116.
11. Yue-Chun L., Li-Sha G., Xue-Qiang G., et al. The mechanism of carvedilol in experimental viral myocarditis. Curr. Pharm. Des. 2012, 18:1620-1624.
12. Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
13. Tardif J.C., O'Meara E., Komajda M., et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur. Heart J. 2011, 32:2507-2515.
14. Dominguez-Rodriguez A., Consuegra-Sanchez L., Blanco-Palacios G., et al. Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Int. J. Cardiol. 2012, 158:160-162.
15. Custodis F., Baumhäkel M., Schlimmer N., et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:2377-2387.
16. f-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur. Heart J. 2012, 33:1223-1231.
17. Walcher T., Bernhardt P., Vasic D., et al. Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration. Mediators Inflamm. 2010, 2010:751313.
18. Yue-Chun L., Teng Z., Na-Dan Z., et al. Comparison of Effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PLoS ONE 2012, 7:e39394.
19. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 1994, 72:561-566.
20. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990, 323:236-241.
21. Mikami S., Kawashima S., Kanazawa K., et al. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem. Biophys. Res. Commun. 1996, 22:983-989.
22. Ishiyama S., Hiroe M., Nishikawa T., et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 1997, 95:489-496.
23. Wang W.Z., Matsumori A., Yamada T., et al. Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation 1997, 95:245-251.
24. Iwasaki A., Matsumori A., Yamada T., et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J. Am. Coll. Cardiol. 1999, 33:1400-1407.
25. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004, 109:1674-1679.
26. Heusch G., Skyschally A., Gres P., et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart J. 2008, 29:2265-2275.
27. Yamada T., Matsumori A., Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994, 89:846-851.
28. Kapadia S.R. Cytokines and heart failure. Cardiol. Rev. 1999, 7:196-206.
29. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 1984, 311:819-823.
30. Lowenstein C.J., Hill S.L., Lafond-Walker A., et al. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 1996, 97:1837-1843.
31. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.